Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M707035200 on October 11, 2007

J. Biol. Chem., Vol. 282, Issue 50, 36377-36385, December 14, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/50/36377    most recent
M707035200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhowmik, S.
Right arrow Articles by Eltis, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhowmik, S.
Right arrow Articles by Eltis, L. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Molecular Basis for Inhibition of BphD, a C-C Bond Hydrolase Involved in Polychlorinated Biphenyls Degradation

LARGE 3-SUBSTITUENTS PREVENT TAUTOMERIZATION*

Shiva Bhowmik{ddagger}1, Geoff P. Horsman§1, Jeffrey T. Bolin{ddagger}2, and Lindsay D. Eltis§3

From the {ddagger}Purdue Cancer Center and Markey Center for Structural Biology, Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907-2054 and the §Departments of Biochemistry and Molecular Biology, and Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

Received for publication, August 22, 2007 , and in revised form, October 3, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The microbial degradation of polychlorinated biphenyls (PCBs) by the biphenyl catabolic (Bph) pathway is limited in part by the pathway's fourth enzyme, BphD. BphD catalyzes an unusual carbon-carbon bond hydrolysis of 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid (HOPDA), in which the substrate is subject to histidine-mediated enol-keto tautomerization prior to hydrolysis. Chlorinated HOPDAs such as 3-Cl HOPDA inhibit BphD. Here we report that BphD preferentially hydrolyzed a series of 3-substituted HOPDAs in the order H > F > Cl > Me, suggesting that catalysis is affected by steric, not electronic, determinants. Transient state kinetic studies performed using wild-type BphD and the hydrolysis-defective S112A variant indicated that large 3-substituents inhibited His-265-catalyzed tautomerization by 5 orders of magnitude. Structural analyses of S112A·3-Cl HOPDA and S112A·3,10-diF HOPDA complexes revealed a non-productive binding mode in which the plane defined by the carbon atoms of the dienoate moiety of HOPDA is nearly orthogonal to that of the proposed keto tautomer observed in the S112A·HOPDA complex. Moreover, in the 3-Cl HOPDA complex, the 2-hydroxo group is moved by 3.6 Å from its position near the catalytic His-265 to hydrogen bond with Arg-190 and access of His-265 is blocked by the 3-Cl substituent. Nonproductive binding may be stabilized by interactions involving the 3-substituent with non-polar side chains. Solvent molecules have poor access to C6 in the S112A·3-Cl HOPDA structure, more consistent with hydrolysis occurring via an acyl-enzyme than a gem-diol intermediate. These results provide insight into engineering BphD for PCB degradation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Polychlorinated biphenyls (PCBs)4 were manufactured extensively in the 20th century for industrial and commercial applications, including use in electrical transformers, hydraulics, and plasticizers.5 Although banned in the United States since 1977, environmentally persistent PCBs have been linked to cancer (2), childhood neurodevelopmental deficits arising from prenatal exposure (3), and a host of other effects attributed to endocrine disruption (4). Indeed, concerns about high concentrations of PCBs and other contaminants in some freshwater fish have prompted a recent comprehensive risk-benefit analysis of fish consumption (5).

The observation that bacteria partially degrade PCBs has motivated research into microbial bioremediation as an alternative to traditional remediation approaches, which typically require the costly and invasive removal of contaminated soil. Bacteria use the biphenyl (Bph) pathway to aerobically degrade many PCBs in a strain-dependent manner. The upper Bph pathway consists of four enzymes that transform biphenyl into benzoic acid and 2-hydroxypenta-2,4-dienoic acid (6). Nevertheless, certain congeners are not efficiently degraded by this pathway, leading to the accumulation of these congeners or their chlorinated metabolites and even inhibition of Bph enzymes. For example, 2',6'-diCl 2,3-dihydroxybiphenyl (2',6'-diCl-DHB) inhibits the third pathway enzyme, DHB dioxygenase (DHBD) in the potent PCB-degrading strain Burkholderia xenovorans LB400 (7). Similarly, 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acids (HOPDAs) that are chlorinated at the 3 and 4 positions inhibit the fourth enzyme, BphD, of B. xenovorans LB400 (8) and Rhodococcus globerulus P6 (8-10) as described below. Interestingly, a glutathione S-transferase in B. xenovorans LB400, BphK, catalyzes the dehalogenation of 3-Cl HOPDA (11) and DxnB2, a homolog of BphD from the dibenzofuran catabolic pathway of Sphingomonas wittichii RW1, catalyzes the hydrolysis of 3-Cl HOPDA (8-10). Nevertheless, chlorinated HOPDAs accumulated in whole cell studies of PCB degradation (12-14), suggesting that BphD represents a bottle-neck for PCB degradation.


Figure 1
View larger version (9K):
[in this window]
[in a new window]

  		FIGURE 1.
The reaction catalyzed by BphD.

 
The inhibition of Bph enzymes has recently taken on additional significance in light of discoveries in Mycobacterium tuberculosis, the etiological agent of tuberculosis. Specifically, homologues of the Bph enzymes are involved in cholesterol catabolism (15) and are critical for the survival of the pathogen in the human macrophage (16). The lack of human homologues of the cholesterol-degrading enzymes suggests that they are promising drug targets. Understanding the mechanism of BphD inhibition will facilitate the engineering of the enzyme to improve its activity toward chlorinated substrates and should inform the development of inhibitors of HsaD, the cholesterol-degrading homologue in M. tuberculosis.

BphD catalyzes the hydrolytic C-C bond cleavage of HOPDA (Fig. 1) and has features typical of the {alpha}/β-hydrolase superfamily (17, 18), including the fold and conserved active site catalytic triad composed of serine, histidine, and aspartate residues. To expel the electron-rich dienoate moiety of the substrate, the enzyme first employs a His-265-mediated enol-keto tautomerization to generate a hydrolyzable keto-intermediate (E·Sk) (19-24). Indeed, His-265-dependent formation of an intermediate with a red-shifted absorbance spectrum (E·Sred) is formed at a similar rate in both WT and S112A BphDs (19). Crystallographic data for the E·Sred intermediate trapped in the S112A·HOPDA complex are most consistent with the bound HOPDA being ketonized (19), although a non-planar, distorted conformation of the enol/enolate could not be completely ruled out. Hydrolysis then proceeds via either a gem-diol intermediate (24-28) or an acyl-enzyme intermediate (19, 20). As noted above, HOPDAs that are chlorinated on the dienoate moiety are poorly transformed by BphD (8-10). Specifically, 5-chlorination reduced the maximal rate of BphD by 3-fold, and chlorination at the 3 or 4 positions reduced the maximal rate by ~103 and ~104-fold, respectively. Although 4-Cl HOPDA is the least efficiently transformed monochlorinated HOPDA, 3-Cl HOPDAs represent a more significant roadblock to PCB degradation in two respects. First, 3-Cl HOPDA (t1/2 ~ 500 h) is more stable than 4-Cl HOPDA, which undergoes a non-enzymatic transformation to 4-OH HOPDA (t1/2 = 2.8 h) followed by degradation to products that include acetophenone (t1/2 ~ 180 h) (8). Second, 3-Cl HOPDA is a very poor substrate of BphDLB400, effectively inhibiting the hydrolysis of HOPDA (Kic = 0.57 µM) more potently than either 4-Cl HOPDA (Kic = 3.6 µM) or 4-OH HOPDA (Kic = 0.95 µM). It has been unclear whether the 3-Cl substituent impairs tautomerization or hydrolysis and whether the defect is due to an electronic or steric effect.

Herein we investigated the basis for inhibition of BphD by 3-Cl HOPDA. First, the ability of BphD to hydrolyze a series of 3-substituted HOPDAs was studied using steady-state kinetics to compare steric versus electronic effects. Second, single turnover stopped-flow kinetic analysis was used to probe the effects of 3-substitution on E·Sred formation in both WT and hydrolytically impaired Ser112Ala variants. Finally, crystal structures of the S112A·3-Cl HOPDA and S112A·3,10-diF-HOPDA complexes were analyzed to reveal the structural correlates of the kinetic behavior.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Chemicals—HOPDA, 3-Cl HOPDA, 3-Me HOPDA, and 3,10-diF HOPDA were enzymatically generated from DHB, 4-Cl DHB, 4-Me DHB, and 4,4'-diF DHB, respectively, using DHBD as previously described (8, 20). The preparation of DHB and chlorinated DHBs has been described elsewhere (29). All other chemicals were of analytical grade.

Preparation of 4,4'-diF DHB—A plate of W medium (30) was streaked with frozen stock of Pandoraea pnomenusa (formerly Comamonas testosteroni) B-356 and incubated with biphenyl crystals in the lid at 30 °C until colonies were visible (~5 days). Several colonies were added to 3 ml of W medium containing 1 mg biphenyl and incubated at 30 °C and 250 rpm until cloudy (~4 days). Alternatively, this step could be shortened to ~2 days if a 50-µl aliquot of frozen stock was used to inoculate the 3 ml of culture. One liter of W medium containing 0.5 g of biphenyl in a 2-liter flask was inoculated with 1 ml of starter culture, and the mixture was incubated as above. When the optical density at 600 nm reached 1, the culture was carefully decanted to remove biphenyl crystals and then centrifuged for 10 min at 7000 x g. The pellet was washed two times with potassium phosphate buffer (I = 0.1 M, pH 7.5) to remove residual biphenyl and resuspended in 500 ml of buffer supplemented with 100 mg of 4,4'-diF-biphenyl and 7 mg of 3-chlorocatechol. The latter was included to inactivate DHBD (31) and thereby prevent enzymatic transformation of the produced 4,4'-diF-DHB. The culture was incubated as above, and 50-µl aliquots were analyzed by high-performance liquid chromatography at 30-min intervals using a Prodigy ODS Prep column, 2.1 x 250 mm (Phenomenex, Torrance, CA), operating at a flow rate of 1.5 ml/min. The mobile phase initially consisted of a 30:70 ratio of solvent A (0.5% aqueous H3PO4) to solvent B (methanol) for the first 5 min of the run, then a gradient was used to achieve 100% B at 10 min. The retention time of 3-chlorocatechol was 2.6 min, 4,4'-diF-DHB eluted at 5.4 min, and 4,4'-diF-biphenyl eluted at 13 min. When the maximum concentration of 4,4'-diF-DHB in the culture was reached as judged by high-performance liquid chromatography (after ~3 h), the culture was filtered to remove undissolved starting material, and then extracted three times with ~200 ml of ethyl acetate. The pooled fractions were dried over anhydrous MgSO4 and rotary evaporated to dryness. The crude extract was dissolved in an appropriate volume of mobile phase (20:80 A:B ratio) and purified by preparative high-performance liquid chromatography using a Prodigy ODS Prep column, 21.2 x 250 mm (Phenomenex, Torrance, CA) operating at a flow rate of 8.5 ml/min. The 4,4'-diF-DHB (retention time ~ 8 min) was collected, extracted into ethyl acetate, dried, and evaporated as above. The purity was estimated to be >95% by high-performance liquid chromatography. The 4,4'-diF-DHB was dissolved in 10% ethanol, 80% H2O, and 10% D2O to collect NMR spectra at 25 °C using a 600-MHz spectrometer at the Department of Chemistry, University of Rochester. The 1H NMR reference compound was 100 µM 2,2-dimethyl-2-silapentane 5-sulfonate and was used as an indirect reference for 19F NMR (found by 19F{1H} NMR: -3.6 (s, 1F), -23.9 (s, 1F)) and 1H NMR (6.75-6.82 (m, 2H), 7.21 (t, 2H, J = 6 Hz), 7.52 (t, 2H, J = 6 Hz)).

Steady-state Kinetic Measurements—Initial rates of BphD-catalyzed hydrolysis at varying substrate concentrations were obtained by monitoring the substrate absorbance maximum versus time in potassium phosphate buffer (I = 0.1 M, pH 7.5) using a Varian Cary 5000 spectrophotometer equipped with a thermostatted cuvette holder (Varian Canada, Mississauga, Ontario, Canada) maintained at 25.0 ± 0.5 °C, controlled by Cary WinUV software version 2.00. Reactions were carried out in a 1-ml volume and were initiated by the addition of 5 µl of an appropriately diluted enzyme solution. The 3-Me HOPDA was generated in situ by adding 80 µg of polyhistidine-tagged DHBD to the cuvette containing 4-Me DHB. After obtaining the rate of background decay (0.5-1 min), BphD was added and the activity of the enzyme was determined by correcting for the background. The Michaelis-Menten equation was fit to the data using LEONORA (32). The molar absorptivity of 3,10-diF HOPDA ({epsilon}438 = 37.9 ± 2.1 mM-1 cm-1) was calculated from its absorption spectrum after quantification by measuring the amount of dioxygen consumed in the ring-opening reaction of 4,4'-diF DHB catalyzed by DHBD. Dioxygen consumption was measured using a Clark-type polarographic oxygen electrode (Yellow Springs Instruments model 5301, Yellow Springs, OH) as previously described for other HOPDAs (33). The molar absorptivity of 3-Me HOPDA ({epsilon}430 = 18.7 ± 0.4 mM-1 cm-1) was determined by recording the absorption spectrum of a known quantity of 4-Me DHB immediately after cleavage by DHBD.

Stopped-flow Spectrophotometry—Single turnover reactions (BphD = 8 µM; substrate = 4 µM) in the phosphate buffer described above were monitored using an SX.18MV stopped-flow reaction analyzer (Applied Photophysics Ltd., Leatherhead, UK) equipped with a photodiode array detector. The drive syringe chamber and optical cell were maintained at 25 °C by a recirculating water system. Multiple wavelength data from the time courses of single shots were acquired using the Xscan software (Applied Photophysics Ltd.), then saved as CSV files in the RISC Pro-K software and exported to Excel where replicate measurements from at least four shots were averaged. Selected single wavelength datasets were then imported into the SX18MV software (Applied Photophysics Ltd.) where multiple exponential equations were fit to the data to obtain reciprocal relaxation times and amplitudes. Good fits were characterized by random variation in the residuals.

Crystallization and Preparation of Complexes—Crystals of the substrate-free S112A variant of BphD were grown at 20 °C in 1.9 M sodium malonate, pH 7.0, by sitting drop vapor diffusion, as previously reported (19). Complexes were prepared by incubating crystals for 30 min in 60 µl of reservoir solution supplemented with ~10 mM 3-Cl-HOPDA or ~65 mM 3,10-difluoro-HOPDA. Crystals were prepared for flash freezing by serial transfer into solutions containing higher concentrations of sodium malonate (3.4 M and 3.7 M, pH 7.0) augmented with ~5 mM of 3-Cl HOPDA or trace amounts of 3,10-difluoro-HOPDA. The incubation time was 3-6 s per step. Crystals were frozen by immersion in liquid N2.

Diffraction Experiments and Structure Analysis—All diffraction data were acquired by the use of the SERCAT facilities at the Advanced Photon Source, Argonne National Laboratory. The x-ray wavelength was 1.0 Å, and crystals were maintained at ~100 K during data collection. Diffraction images were recorded by a MarMosaic 300 charge-coupled device detector (Mar USA, Inc., Evanston, IL). For each crystal, ~100 frames were collected with a 1° rotation per frame; exposure times were 1-10 s per degree. All images were processed using DENZO, and intensities were merged and scaled using SCALEPACK; both programs were from the HKL2000 program suite (34).

The initial model for both complexes included only the protein atoms from the crystal structure of the S112A·malonate complex (PDB code 2PU6) (19). Rigid body refinement performed in REFMAC (35) from the CCP4 package (36) was followed by iterative cycles of restrained atomic parameter refinement via REFMAC and manual density fitting using the molecular graphics program O (37). PRODRG (38) was used to construct structures of 3-Cl HOPDA, 3,10-difluoro-HODPA, and malonate for density fitting and establishment of refinement restraints. The bond lengths and bond angles of the ligands were restrained to values expected for the enol isomer. Torsion angles in the non-aromatic portion of the substrates were unrestrained. The stereochemical properties of the models and the hydrogen bonding were analyzed by using the programs PROCHECK (39) and REDUCE (40).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Steady-state Kinetics—To assess the basis of inhibition of BphD by 3-Cl HOPDA, the enzyme-catalyzed hydrolysis of 3,10-diF HOPDA and 3-Me HOPDA was studied using steady-state kinetics. The 10-fluoro substituent is not expected to greatly affect catalysis because HOPDAs with small, electron-withdrawing substituents (e.g. -Cl and -CF3) at this position are hydrolyzed by BphD with kcat values within 25% of that for HOPDA (8, 28). Significantly, reduction of the volume of the electronegative 3-substituent by 40% upon chlorine-to-fluorine substitution resulted in a 150-fold increase in kcat (Table 1), indicating that larger 3-substituents interfere with catalysis. This conclusion was supported by the observation that the substrate with the largest 3-substituent, 3-Me HOPDA, had the lowest apparent kcat (Table 1). Although a Km value was reported for 3-Cl HOPDA (8), Km could not be determined for 3-Me HOPDA due to a combination of lower activity, lower molar absorptivity, and higher background decay rates, which together prevented reliable initial rate measurements at low substrate concentrations. Finally, we also determined the stability of HOPDAs in the enzyme reaction buffer (Table 1), but we discerned no obvious correlation between either the electronegativity of the substituents and the nonenzymatic decomposition, or between the nonenzymatic and enzymatic reactions. In conclusion, kcat was strongly anticorrelated with the volume of the substituent at C3 and uncorrelated with electronegativity over the series of HOPDAs studied, suggesting that turnover is largely dictated by steric, not electronic, factors.


View this table:
[in this window]
[in a new window]

  		TABLE 1
Steady-state parameters of BphD hydrolysis of 3-substituted HOPDAs Errors are less than 15%.

 


Figure 2
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 2.
Time-resolved spectra from single turnover (E = 8 µM;S = 4 µM) stopped-flow spectrophotometry show that increasing the size of the HOPDA 3-substituent limits accumulation of the high wavelength-absorbing E·Sred intermediate. Reactions are shown for wild-type BphD (WT, left panels) and S112A (right panels) with 3-Cl HOPDA (top), 3,10-diF HOPDA (middle), and HOPDA (bottom). A, wild type plus 3-Cl HOPDA; B, S112A plus 3-Cl HOPDA; C, wild type plus 3,10-diF HOPDA; D, S112A plus 3,10-diF HOPDA; E, wild type plus HOPDA, from Ref. 20; and F, S112A plus HOPDA, from Ref. 19. Arrows indicate the direction of absorbance changes with time. Separate relaxations are indicated by numbered arrows, and correspond to the phases described in Table 2.

 
Stopped-flow Kinetics—To better elucidate the influence of 3-substituents on catalysis, stopped-flow experiments were conducted to resolve individual catalytic steps. In a previous single turnover ([E] > [S]) stopped-flow experiment using WT BphD and HOPDA, we observed rapid (~500 s-1) formation of E·Sred ({lambda}max = 492 nm) from the free HOPDA enolate ({lambda}max = 434 nm) (Fig. 2E) (20). A similar E·Sred intermediate ({lambda}max = 506 nm) was rapidly formed (~500 s-1) and trapped in the hydrolytically impaired S112A variant (Fig. 2F), and crystallographically was observed in a non-planar conformation (19). In contrast, E·Sred did not accumulate when 3-Cl HOPDA was used as a substrate (Fig. 2A). Under single turnover conditions ([BphD] = 8 µM, [3-Cl HOPDA] = 4 µM), an initial decrease (1/{tau}1 = 15 s-1) occurred at the absorbance maximum of the 3-Cl HOPDA enolate (432 nm) (Table 2). This decay corresponded to a ~20% loss in absorbance and occurred together with a slight blue shift to 427 nm. This may correspond to formation of an enzyme-bound planar 3-Cl HOPDA enolate, E·Se. This species very slowly decayed (1/{tau}2 = 0.0077 s-1) at a rate that matches the previously measured kcat value (Table 1). Interestingly, this rate is similar to that of tautomerization of HOPDA in solution as measured by deuterium exchange experiments (20, 22). The absence of E·Sred accumulation suggests that 3-Cl HOPDA tautomerization is slower than hydrolysis.


View this table:
[in this window]
[in a new window]

  		TABLE 2
Reciprocal relaxation times and amplitudes for single turnover reactions monitored by stopped-flow spectrophotometry at the substrate absorption maxima The 3-Cl HOPDA reaction was monitored at 432 nm; 3,10-diF HOPDA was monitored at 438 nm. Errors are no more than 15%.

 
In an attempt to observe E·Sred accumulation for 3-Cl HOPDA, the S112A variant was used. This variant catalyzes E·Sred formation at the same rate as WT BphD but possesses severely impaired hydrolytic activity (19). For 3-Cl HOPDA, E·Sred did not detectably accumulate in this variant (Fig. 2B). Similar to the behavior of WT, S112A caused an initial decrease (1/{tau}1 = 26 s-1) corresponding to ~15% loss in 3-Cl HOPDA absorbance (Table 2), albeit without a correlated blue shift. This was followed by a very small (<1% of total 3-Cl HOPDA absorbance) and relatively slow (1/{tau}2 = 0.55 s-1) increase in absorbance at 432 nm. Subsequent decay was not detected on the time scale examined (<1 min). In summary, an E·Sred species of 3-Cl HOPDA was not detected in either wild type or S112A, suggesting that an E·Se complex is the predominant enzyme-bound species and that catalysis is limited by formation of E·Sred.

The improved turnover of 3,10-diF HOPDA compared with 3-Cl HOPDA (Table 1) implies that 3,10-diF HOPDA may be more readily ketonized by the enzyme. The reaction of BphD with 3,10-diF HOPDA yielded a detectable E·Sred ({lambda}max ~ 468 nm, Fig. 2C). The low intensity of this spectrum suggests that only a small amount of E·Sred accumulates, and thus tautomerization may be only partially rate-limiting. Decay of the signal at the absorbance maximum of 3,10-diF HOPDA (438 nm) can be described by three phases (Table 2): (i) a loss in absorbance (1/{tau}1 = 51 s-1) analogous to the initial decay in the 3-Cl HOPDA reaction, whereby a slightly blue-shifted feature ({lambda}max = 427 nm) was generated together with a ~30% loss in absorbance; (ii) a small (20% of total absorbance decrease) second decay (1/{tau}2 = 7.6 s-1) that generated E·Sred ({lambda}max ~ 468 nm), and (iii) a final phase, 1/{tau}3 = 1.3 s-1.

Although E·Sred ({lambda}max ~ 517 nm) accumulated to a greater extent in S112A than in wild type, stoichiometric formation of this species was not observed using 3,10-diF HOPDA (Fig. 2D). E·Sred is formed quickly (1/{tau}1 = 90 s-1), but consumes only ~35% of the substrate based on absorbance. This is followed by a minor relaxation of <1% total absorbance, which occurs as an increase at 438 nm (1/{tau}2 = 1.1 s-1) and a corresponding decrease at 517 nm. The incomplete E·Sred formation suggests that the 3-F substituent destabilizes E·Sred relative to the E·Se complex and/or free substrate. Curiously, 3,10-diF HOPDA E·Sred formation is faster in S112A than wild type, suggesting that the Ser-112 hydroxyl function may impede tautomerization by further stabilizing the E·Se complex relative to E·Sred.

In summary, increasing the size of the 3-substituent appears to slow E·Sred formation. The fluoro-substitution apparently slows tautomerization by similarly stabilizing both E·Sred and an alternate E·Se binding mode. Although E·Sred accumulation is minimal, tautomerization is not significantly slowed relative to hydrolysis, and therefore the overall rate of catalysis is not dramatically affected. In contrast, tautomerization is more severely impaired by chloro-substitution, which may preferentially stabilize E·Se relative to E·Sred.

Crystal Structure of S112A·3-Cl HOPDA—The crystal structure of the binary complex of S112A with 3-Cl HOPDA was examined at 1.7 Å resolution. Tables 3 and 4 summarize the diffraction data and refinement statistics, respectively. With respect to the fold of the monomer and quaternary structure, the protein structure exhibits no important differences relative to the malonate (PDB entry 2PU6) and HOPDA complexes (PDB entry 2PUH) of S112A; these conclusions are also valid for the structure of the 3,10-diF HOPDA complex described below.


View this table:
[in this window]
[in a new window]

  		TABLE 3
Crystal properties and x-ray diffraction data for S112A complexes

 


View this table:
[in this window]
[in a new window]

  		TABLE 4
Results of refinement for BphD-S112A complexes

 
The binding of 3-Cl HOPDA to S112A and related electron density maps are illustrated in Fig. 3A. As shown in Fig. 3A, Fo-Fc maps, calculated before the substrate was added to the model, contained readily interpretable electron density for 3-Cl-HOPDA, which was modeled as the enol isomer, (2Z,4E)-3-Cl HOPDA, because the kinetic experiments did not detect accumulation of a species corresponding to Sred in solution. Nevertheless, the nearly coplanar conformation of 3-Cl-HOPDA cannot exclude the presence of the keto isomer: the torsion angles do not uniquely predict which bonds are single and which are double.

Fig. 3B shows that 3-Cl HOPDA and HOPDA bind in distinctly different conformations and slightly different overall positions. Thus, although the dienoate moiety, the 6-oxo group, and the 6-phenyl substituent occupy the same binding sites in the two complexes, the root mean square deviation is 0.86 Å for the common atoms of the two ligands. Likewise, several interacting protein side chains, especially those of Asn-111, Met-171, Phe-175, Trp-266, and His-265, are in significantly different positions/conformations in the two complexes. These variations largely reflect a gross difference in the orientation of the dienoate moiety relative to the protein. In essence, the planes defined by atoms C1 through C5 in the two complexes are nearly orthogonal to each other, and the torsion angles about the C2-C3 and C1-C2 bonds differ by 155° and 90°, respectively.


Figure 3
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 3.
Comparison of the binding of 3-Cl HOPDA and HOPDA to S112A. A, stereoscopic view showing: the refined model of S112A·3-Cl HOPDA complex; the 2Fo-Fc electron density of the refined structure (cyan, contour level = 1{sigma}); and the Fo-Fc electron density before 3-Cl-HOPDA was added to the model (blue, contour level = 3{sigma}). The carbon atoms of Ala-112, Asp-237, and His-265 are colored brown, whereas carbon atoms in other protein residues and in the ligand are gold. N, O, S, and Cl atoms are colored blue, red, yellow, and green, respectively. B, stereoscopic view of superposed models for S112A·3-Cl-HOPDA and S112A·HOPDA emphasizing the active site. All carbon atoms and covalent bonds are colored in gold for S112A·3-Cl-HOPDA and in gray for S112A·HOPDA. Other atoms are colored as in A. C, stereoscopic view of S112A·3-Cl-HOPDA emphasizing interactions between the 3-Cl substituent and the protein. The dotted lines mark the closest approach to side-chain atoms of Leu-156, Met-171, Phe-175, and Phe-239. The labels include contact distances in Angstroms.

 
In consequence, the binding interactions of the 1-carboxylate and 2-hydroxo groups of 3-Cl HOPDA are remarkably different relative to those observed in the HOPDA complex. Dominant features of HOPDA binding include hydrogen bonds between both oxygen atoms of the 1-carboxylate group and the guanidinium group of conserved Arg-190, and a hydrogen bond between the 2-oxo/hydroxo oxygen and the side chain of His-265. Although the 1-carboxylate group of 3-Cl HOPDA is in the vicinity of Arg-190, it does not hydrogen bond with that residue. Rather, the 2-hydroxo group is moved by 3.6 Å from its position near His-265 in the S112A·HOPDA complex and hydrogen bonds with Arg-190. The Z conformation about the C2-C3 bond places the 3-Cl atom in an adjacent binding site formed by the non-polar side chains of Leu-156, Phe-175, and Phe-239 (see Fig. 3C), and at longer distances by the side chains of Pro-44 and Met-171, which is found in alternate conformations. Moreover, the chlorine atom and the side chain of Phe-175 lie between His-265 and the 2-hydroxyl group.

Accommodation of the bulky 3-Cl substituent in an appropriate non-polar site appears to be the major cause of the differences in conformation and position of 3-Cl HOPDA relative to HOPDA as well as adjustments of the protein. If 3-Cl HOPDA assumed the conformation and position of HOPDA in the crystal structure of its complex with S112A, the 3-Cl group would be in steric conflict with the backbone nitrogens of Gly-42 and Gly-43 (distances of <2.4 Å) and the 6-oxo-substituent (2.5 Å). Similarly, when the coordinates for 3-Cl HOPDA are mapped onto the HOPDA complex, the chlorine atom is placed 2.1 Å from the C{zeta} of Phe-175. Relaxation of the latter contact may motivate the observed differences in the conformations of His-265, Trp-266, as well as other nearby residues.

At least four characteristic features of the HOPDA complex are reproduced in the 3-Cl HOPDA complex: 1) the 6-oxo group binds in the oxyanion hole formed by backbone amides of Gly-42 and Met-113; 2) C5 and C6 remain within 3.8 Å of the Cβ atom of Ala-112; 3) there is inadequate room in the active site for a water molecule to approach C6 from either face; and 4) the 6-phenyl substituent interacts with the same non-polar side chains of the NP-site, including those of Ile-153, Leu-213, Trp-216, and Val-240. With respect to point 3, the substrate binding site includes no crystallographically ordered waters and no water-sized voids. The closest ordered water is 7.5 Å away from C6 and lies in a solvent-accessible pocket beyond the phenyl substituent.

The electron density maps also suggest an additional, minor binding mode in which the phenyl substituent occupies the expected binding site, but in a different orientation, and the rest of the ligand extends away from the catalytic residues toward a possible entrance to the active site near the side chains of Phe-157, Ala-208, and Pro-212. This mode was not modeled.

Crystal Structure of S112A·3,10-diF HOPDA—Although the crystal structure of S112A·3,10-diF HOPDA was determined at higher resolution than the 3-Cl HOPDA complex (1.57 Å versus 1.7 Å; see Tables 3 and 4), the development of a definitive model for the ligand proved to be more difficult. As described below, the assessment of many electron density maps and refinement experiments led us to conclude that the C1-carboxylate and C2-hydroxyl substituents bind in multiple, poorly resolved conformations. The final model includes 3,10-diF HOPDA in a single conformation that represents the most reliable observations and is similar to the conformation of 3-Cl HOPDA.

Fo - Fc difference maps prior to the addition of any HOPDA atoms showed continuous density commensurate with the entire ligand only at a relatively low contour level (+2{sigma}, where {sigma} is the standard deviation from a mean of 0 e-/Å3). In addition, the density was of inconsistent quality: features near the center of the binding site and corresponding to the expected positions of C5, C6, the 6-oxo group, and a few atoms of the 6-phenyl substituent were strong and well resolved, whereas the features for the more distal atoms of the phenyl ring and the dienoate moiety were weak and poorly resolved. The better density overlaps the known binding site for malonate, a major component of the mother liquor and all stabilization solutions. Thus, a difference map was calculated with coefficients Formula - Formula and phases from the structure of the malonate complex to validate the binding of 3,10-diF HOPDA and assess its conformation. This map unequivocally defined the p-fluorophenyl substituent (i.e. 10-F). Positive density was also observed in the region occupied by C2, C3, the 3-Cl substituent, and the carboxylate in the 3-Cl HOPDA complex, but the 2-OH group was not defined and the carboxylate group was poorly resolved. Similar features were observed in difference maps based on 2.0-Å resolution data acquired from a second S112A·3,10-diF HOPDA crystal using a CuK{alpha} rotating anode x-ray source (data not shown).

From these observations, 3,10-diF-HOPDA was modeled and refined with the dienoate moiety in the same 2Z,4E conformation as 3-Cl HOPDA. The resulting Fo - Fc maps suggested an alternative location for the carboxylate group consistent with a 2E,4E conformer. To test this observation, maps were calculated with coefficients (Formula - Formula) and phases from the 3-Cl HOPDA complex using data from two S112A·3,10-diF HOPDA crystals. Both maps had negative features overlapping the carboxylate, 2-OH, and 3-Cl groups of 3-Cl HOPDA, and a positive feature confirming the 10-F substituent of diF-HOPDA (a negative peak is expected at the chlorine atom even if F occupies the same position because of the difference in atomic scattering power). There was no comparable difference density near C5, C6, and most of the atoms of the phenyl ring, indicating these portions of the HOPDA structure are consistently located in the diF-HOPDA and 3-Cl HOPDA complexes. These maps also had minor positive and negative features indicating that malonate was bound in a significant fraction of the active sites in the S112A·diF HOPDA crystals, as it is bound in the previously determined structure of S112A·malonate. The presence of malonate-associated density inhibited confirmation of the location of the 2-OH group as its expected location in the 2E,4E conformer is within 1.3 Å of the location of one of the oxygen atoms of malonate. Maps with coefficients (Formula - Formula), x <= 1.0, were calculated to obtain the equivalent of an Fobs map with the contribution of the malonate removed and to estimate the fractional occupancy of 3,10-diF HOPDA. These maps also failed to establish the location of the 2-OH group or resolve the carboxylate group.

Based on this evidence, 3,10-diF HOPDA was ultimately modeled and refined at 60% occupancy as the 2Z,4E conformer in a conformation similar to that of 3-Cl HOPDA. We also tested all possible 2E,4E and 2Z,4E conformations and found none to be as compatible with the electron density. Taken as a whole, the electron density maps indicate the final model does not provide a full description of the active site structure and lead us to conclude that 3,10-diF HOPDA accesses multiple conformations in the crystal.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The molecular basis for the inhibition of BphD by 3-Cl HOPDA was studied by steady-state and transient-state kinetics, and x-ray crystallographic analysis of E·S complexes of 3-substituted HOPDAs. These studies revealed that (i) steady-state turnover is limited by steric, not electronic, features of the 3-substituent; (ii) large 3-substituents impair E·Sred formation, and therefore tautomerization; and (iii) 3-substituted HOPDAs bind in a non-productive mode.

Steady-state kinetic studies demonstrated that steric bulk, not electronegativity, of the 3-substituent obstructs BphD catalysis. Incremental increases in the size of the 3-substituent incrementally slowed turnover: the enzyme preferentially hydrolyzed 3-substituted HOPDAs in the order H > F > Cl > Me. By contrast, there was no significant correlation between turnover and electronegativity of the 3-substituent. Stopped-flow spectrophotometry demonstrated that larger 3-substituents impede formation of the E·Sred intermediate. For instance, whereas E·Sred is apparently completely formed from HOPDA, minor accumulation occurred from 3,10-diF HOPDA, and this intermediate was not detected when 3-Cl HOPDA was used as a substrate. Thus, large 3-substituents inhibit the formation of E·Sred and ultimately disrupt tautomerization.

The kinetic data predict a non-productive binding mode for 3-substituted HOPDAs. For 3-Cl HOPDA, stopped-flow analysis reveals a two-step transformation: initial formation of an E·Se intermediate (1/{tau}1 = 15 s-1), followed by its decay (1/{tau}2 = 0.0077 s-1) to products, possibly via rate-determining formation of E·Sred. For 3,10-diF HOPDA, a similar initial formation of E·Se (1/{tau}1 = 51 s-1) was followed by two slower relaxations (1/{tau}2 = 7.6 s-1 and 1/{tau}3 = 1.3 s-1) during which a small amount of E·Sred appeared to accumulate. The incomplete E·Sred formation for S112A·3,10-diF HOPDA implies reversibility and suggests that the mechanism may be described by either three-step model in Fig. 4.

The S112A·3-Cl HOPDA crystal structure is consistent with the kinetic data, indicating that the 3-Cl HOPDA is bound nonproductively. More specifically, the structure reveals a substrate-binding mode (Fig. 3) wherein 3-Cl HOPDA binds in a C1-C6 coplanar conformation with the plane of the dienoate moiety orthogonal to that of the E·Sred intermediate of the S112A·HOPDA complex (19). Although the crystallographic studies cannot determine the tautomeric state of the ligand in this case, the observed binding mode is consistent with the impaired E·Sred formation of 3-Cl HOPDA observed by stopped-flow. In addition, the conformation is very similar to that observed for HOPDA in the complex with the S112A/H265A mutant, which does not accumulate E·Sred. The C1-carboxylate and C2-hydroxyl groups of 3-Cl HOPDA are in remarkably different positions relative to those observed for E·Sred in the same S112A variant. Whereas both oxygen atoms of the HOPDA C1-carboxylate group hydrogen bond with the guanidinium group of Arg-190, this residue instead hydrogen bonds to the 2-oxo/hydroxyl group of 3-Cl HOPDA. As a result, the hydrogen bond between the 2-oxo/hydroxyl oxygen and the side chain of His-265 observed in the S112A complex with HOPDA is not possible for 3-Cl HOPDA. The crystal structure therefore illustrates that the preferred binding mode of 3-Cl HOPDA is incompatible with the proposed His-265-mediated proton transfer of the tautomerization reaction.


Figure 4
View larger version (5K):
[in this window]
[in a new window]

  		FIGURE 4.
Possible kinetic schemes for BphD-catalyzed hydrolysis of 3,10-diF HOPDA.

 


Figure 5
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 5.
The proposed effect of 3-substituent size on tautomerization. H.P. = hydrophobic pocket. Boxes enclose structures that were crystallographically observed in the hydrolytically impaired S112A enzyme. Although the protonation state of E·Se is not known, the absorption spectrum is most consistent with an enzyme-bound enolate.

 
In light of the different isomeric states and binding modes of 3-Cl HOPDA and HOPDA to S112A, it is remarkable that the structures of neither complex contain a solvent molecule suitable for attack of the E·S C6 carbonyl in the active site, despite the extra space made available by removal of the serine hydroxyl: the closest water is more than 7 Å away. In this respect, the crystal structure of the S112A·3-Cl HOPDA complex is more consistent with a nucleophilic role for Ser-112.

The crystal structures also provide a possible explanation for the greater accumulation of E·Se for 3-Cl HOPDA relative to 3,10-diF HOPDA (Fig. 3C). The 3-Cl atom occupies a binding pocket formed by the non-polar side chains of Leu-156, Phe-175, Phe-239, and Met-171. Because these residues do not shift as a result of Ser-112 substitution, this binding pocket is probably available and also utilized in the wild-type enzyme. It is possible that the compatibility of chlorine versus fluorine with this hydrophobic pocket versus the solution may account for the greater accumulation of 3-Cl HOPDA in the E·Se binding mode, although this may also reflect the inability of 3-Cl HOPDA to access the E·Sred conformation, as discussed below. Similarly, acetylcholine esterase binds huprine X such that a hydrophobic pocket is fully occupied by the inhibitor's chlorine atom, and substitution with fluorine reduces binding affinity (41, 42). In the crystal, the binding of 3-Cl HOPDA is also monomorphic, whereas the carboxylate, 2-OH, and 3-F moieties of 3,10-diF HOPDA are not well ordered. This may reflect a difference in binding forces and/or a difference in the interaction between the 2-OH and 3X groups in the 2Z conformation.

The proposed effects of 3-substituted HOPDAs on formation of the catalytically competent E·Sred are summarized in Fig. 5. Unsubstituted HOPDA is rapidly converted to E·Sred under single turnover conditions (1/{tau}1 ~ 500 s-1), and the presence of an isosbestic point at ~460 nm suggests direct transformation (19, 20). Large 3-substituents may stabilize an alternate planar E·Se binding mode in which the 3-substituent occupies a hydrophobic pocket. In contrast, large 3-substituents are predicted to destabilize the non-planar E·Sred conformation via a steric clash with the backbone of Gly-43 and/or an intramolecular steric conflict with other HOPDA atoms. Thus, access to E·Sred is more severely impaired for 3-Cl HOPDA than for 3,10-diF HOPDA. Interestingly, the possibility of moderate destabilization of both E·Se and E·Sred by the 3-F substituent is consistent with the S112A·3,10-diF HOPDA crystal structure indicating multiple binding modes for the carboxylate and 2-OH groups. Nevertheless, the association of the 6-oxo group with the oxyanion hole is maintained, which allows the scissile bond to approach the His-265 and Ser/Ala-112 residues involved in hydrolysis. Although kinetic constants were not determined for 3-Me HOPDA, the volume of the methyl substituent is only ~25% larger than chlorine, so it may also occupy the hydrophobic pocket.

The preference for 3-Cl HOPDA binding in the alternate planar E·Se mode instead of generating the productive, nonplanar E·Sred intermediate has implications for both bioremediation of PCBs and the development of tuberculosis therapeutics. With respect to the former, the ability of the BphD homologue DxnB2 to hydrolyze 3-Cl HOPDA with a ~13-fold higher specificity may provide an opportunity to overcome this block in the Bph pathway (9). Nevertheless, the structural basis for the different activities of these enzymes is unclear: Gly-42 and Gly-43, which are proposed to clash with the 3-Cl substituent in the E·Sred conformation, as well as the flanking residues are conserved between the two enzymes, as is Phe-74, the residue closest in space to Gly-43. Further studies of DxnB2 should reveal the basis for its improved turnover of 3-Cl HOPDA and may further guide protein-engineering efforts.


   FOOTNOTES
 
The atomic coordinates and structure factors (code 2RHT, 2RHW) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by a grant from the Natural Sciences and Engineering Research Council of Canada (Discovery grant to L. D. E.). X-ray diffraction data were collected at SE Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the U. S. Dept. of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Both authors contributed equally to this work. Back

2 To whom correspondence may be addressed: 915 W. State St., West Lafayette, IN 47907. Tel.: 765-494-4408; Fax: 765-494-0876; E-mail: jtb{at}purdue.edu. 3 To whom correspondence may be addressed: 1365-2350, Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Tel.: 604-822-0042; Fax: 604-822-6041; E-mail: leltis{at}interchange.ubc.ca.

4 The abbreviations used are: PCB, polychlorinated biphenyl; Bph, biphenyl; DHB, dihydroxybiphenyl; DHBD, DHB dioxygenase; HOPDA, 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid; WT, wild type. Back

5 U. S. Environmental Protection Agency (Oct. 24, 2007) Polychlorinated biphenyls (PCBs) (Oct. 24, 2007) http://www.epa.gov/epaoswer/hazwaste/pcbs/index.htm. Back


   ACKNOWLEDGMENTS
 
We thank Sally Rocks (University of Rochester) for obtaining NMR spectra.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Cruickshank, D. W. J. (1999) Acta Crystallogr. Sect. D Biol. Crystallogr. 55, 583-601[CrossRef][Medline] [Order article via Infotrieve]
  2. Knerr, S., and Schrenk, D. (2006) Crit. Rev. Toxicol. 36, 663-694[CrossRef][Medline] [Order article via Infotrieve]
  3. Jacobson, J. L., and Jacobson, S. W. (1996) N. Engl. J. Med. 335, 783-789[Abstract/Free Full Text]
  4. Toft, G., Hagmar, L., Giwercman, A., and Bonde, J. P. (2004) Reprod. Toxicol. 19, 5-26[CrossRef][Medline] [Order article via Infotrieve]
  5. Mozaffarian, D., and Rimm, E. B. (2006) J. Am. Med. Assoc. 296, 1885-1899[Abstract/Free Full Text]
  6. Pieper, D. H. (2005) Appl. Microbiol. Biotechnol. 67, 170-191[CrossRef][Medline] [Order article via Infotrieve]
  7. Dai, S. D., Vaillancourt, F. H., Maaroufi, H., Drouin, H. M., Neau, D. B., Snieckus, V., Bolin, J. T., and Eltis, L. D. (2002) Nat. Struct. Biol. 9, 934-939[CrossRef][Medline] [Order article via Infotrieve]
  8. Seah, S. Y. K., Labbé, G., Nerdinger, S., Johnson, M. R., Snieckus, V., and Eltis, L. D. (2000) J. Biol. Chem. 275, 15701-15708[Abstract/Free Full Text]
  9. Seah, S. Y. K., Ke, J., Denis, G., Horsman, G. P., Fortin, P. D., Whiting, C. J., and Eltis, L. D. (2007) J. Bacteriol. 189, 4038-4045[Abstract/Free Full Text]
  10. Seah, S. Y. K., Labbé, G., Kaschabek, S. R., Reifenrath, F., Reineke, W., and Eltis, L. D. (2001) J. Bacteriol. 183, 1511-1516[Abstract/Free Full Text]
  11. Fortin, P. D., Horsman, G. P., Yang, H. M., and Eltis, L. D. (2006) J. Bacteriol. 188, 4424-4430[Abstract/Free Full Text]
  12. Furukawa, K., Tomizuka, N., and Kamibayashi, A. (1979) Appl. Environ. Microb. 38, 301-310[Abstract/Free Full Text]
  13. Furukawa, K., Tonomura, K., and Kamibayashi, A. (1978) Appl. Environ. Microb. 35, 223-227[Abstract/Free Full Text]
  14. Seeger, M., Timmis, K. N., and Hofer, B. (1995) Appl. Environ. Microb. 61, 2654-2658[Abstract]
  15. Van der Geize, R., Yam, K., Heuser, T., Wilbrink, M. H., Hara, H., Anderton, M. C., Sim, E., Dijkhuizen, L., Davies, J. E., Mohn, W. W., and Eltis, L. D. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 1947-1952[Abstract/Free Full Text]
  16. Rengarajan, J., Bloom, B. R., and Rubin, E. J. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 8327-8332[Abstract/Free Full Text]
  17. Holmquist, M. (2000) Curr. Prot. Pept. Sci. 1, 209-235[CrossRef]
  18. Ollis, D. L., Cheah, E., Cygler, M., Dijkstra, B., Frolow, F., Franken, S. M., Harel, M., Remington, S. J., Silman, I., Schrag, J., Sussman, J. L., Verscheuren, K. H. G., and Goldman, A. (1992) Protein Eng. 5, 197-211[Abstract/Free Full Text]
  19. Horsman, G. P., Bhowmik, S., Seah, S. Y. K., Kumar, P., Bolin, J. T., and Eltis, L. D. (2007) J. Biol. Chem. 282, 19894-19904[Abstract/Free Full Text]
  20. Horsman, G. P., Ke, J., Dai, S., Seah, S. Y. K., Bolin, J. T., and Eltis, L. D. (2006) Biochemistry 45, 11071-11086[CrossRef][Medline] [Order article via Infotrieve]
  21. Henderson, I. M. J., and Bugg, T. D. H. (1997) Biochemistry 36, 12252-12258[CrossRef][Medline] [Order article via Infotrieve]
  22. Lam, W. W. Y., and Bugg, T. D. H. (1997) Biochemistry 36, 12242-12251[CrossRef][Medline] [Order article via Infotrieve]
  23. Li, C., Montgomery, M. G., Mohammed, F., Li, J. J., Wood, S. P., and Bugg, T. D. H. (2005) J. Mol. Biol. 346, 241-251[CrossRef][Medline] [Order article via Infotrieve]
  24. Li, J. J., Li, C., Blindauer, C. A., and Bugg, T. D. H. (2006) Biochemistry 45, 12461-12469[CrossRef][Medline] [Order article via Infotrieve]
  25. Fleming, S. M., Robertson, T. A., Langley, G. J., and Bugg, T. D. H. (2000) Biochemistry 39, 1522-1531[CrossRef][Medline] [Order article via Infotrieve]
  26. Li, J. J., and Bugg, T. D. H. (2007) Org. Biomol. Chem. 5, 507-513[CrossRef][Medline] [Order article via Infotrieve]
  27. Speare, D. M., Fleming, S. M., Beckett, M. N., Li, J. J., and Bugg, T. D. H. (2004) Org. Biomol. Chem. 2, 2942-2950[CrossRef][Medline] [Order article via Infotrieve]
  28. Speare, D. M., Olf, P., and Bugg, T. D. H. (2002) Chem. Commun. 2304-2305
  29. Nerdinger, S., Kendall, C., Marchhart, R., Riebel, P., Johnson, M. R., Yin, C. F., Eltis, L. D., and Snieckus, V. (1999) Chem. Commun. 2259-2260
  30. Seto, M., Kimbara, K., Shimura, M., Hatta, T., Fukuda, M., and Yano, K. (1995) Appl. Environ. Microb. 61, 3353-3358[Abstract]
  31. Vaillancourt, F. H., Labbe, G., Drouin, N. M., Fortin, P. D., and Eltis, L. D. (2002) J. Biol. Chem. 277, 2019-2027[Abstract/Free Full Text]
  32. Cornish-Bowden, A. (1995) Analysis of Enzyme Kinetic Data, Oxford University Press, New York
  33. Seah, S. Y. K., Terracina, G., Bolin, J. T., Riebel, P., Snieckus, V., and Eltis, L. D. (1998) J. Biol. Chem. 273, 22943-22949[Abstract/Free Full Text]
  34. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307-326[CrossRef]
  35. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Acta Crystallogr. Sect. D Biol. Crystallogr. 53, 240-255[CrossRef][Medline] [Order article via Infotrieve]
  36. Bailey, S. (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760-763[CrossRef][Medline] [Order article via Infotrieve]
  37. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. A 47, 110-119[CrossRef]
  38. Schuttelkopf, A. W., and van Aalten, D. M. F. (2004) Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 1355-1363[CrossRef][Medline] [Order article via Infotrieve]
  39. Laskowski, R., MacArthur, M., Moss, D., and Thornton, J. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef]
  40. Word, J. M., Lovell, S. C., Richardson, J. S., and Richardson, D. C. (1999) J. Mol. Biol. 285, 1735-1747[CrossRef][Medline] [Order article via Infotrieve]
  41. Camps, P., El Achab, R., Gorbig, D. M., Morral, J., Munoz-Torrero, D., Badia, A., Banos, J. E., Vivas, N. M., Barril, X., Orozco, M., and Luque, F. J. (1999) J. Med. Chem. 42, 3227-3242[CrossRef][Medline] [Order article via Infotrieve]
  42. Dvir, H., Wong, D. M., Harel, M., Barril, X., Orozco, M., Luque, F. J., Munoz-Torrero, D., Camps, P., Rosenberry, T. L., Silman, I., and Sussman, J. L. (2002) Biochemistry 41, 2970-2981[CrossRef][Medline] [Order article via Infotrieve]
  43. Allred, A. L., and Rochow, E. G. (1958) J. Inorg. Nucl. Chem. 5, 215-221
  44. Zhao, Y. H., Abraham, M. H., and Zissimos, A. M. (2003) J. Org. Chem. 68, 7368-7373[CrossRef][Medline] [Order article via Infotrieve]
  45. Allen, F. H., Kennard, O., Watson, D. G., Brammer, L., Orpen, A. G., and Taylor, R. (1987) J. Chem. Soc. Perkin Trans. 2, S1-S19
  46. Liu, H., Wang, Q. W., and Liu, L. X. (1992) J. Chem. Educ. 69, 783-784

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/50/36377    most recent
M707035200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhowmik, S.
Right arrow Articles by Eltis, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhowmik, S.
Right arrow Articles by Eltis, L. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement